Related Experiment Videos

Suppression of default apoptosis in androgen-dependent cells by testosterone-mediated bcl-2 expression

T Ohigashi1, M Ueno, M Iida

  • 1Department of Urology, Saitama Medical School, Japan. ohigashi@med.keio.ac.jp

Abstract

Insights

The bcl-2 proto-oncogene inhibits apoptosis in androgen-dependent cells. Antisense therapy targeting bcl-2 may offer a new treatment for hormone-refractory prostate cancer.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Oncology

Background:

  • The role of apoptosis in androgen-dependent cell development and progression remains unclear.
  • Investigating the bcl-2 proto-oncogene's expression and function in androgen deprivation is crucial.

Purpose of the Study:

  • To examine bcl-2 proto-oncogene expression in androgen-dependent cells following androgen deprivation.
  • To elucidate the role of bcl-2 in cell growth and apoptosis in an androgen-dependent cell line.

Main Methods:

  • Utilized the SC2G mouse mammary carcinoma cell line.
  • Measured bcl-2 mRNA and protein levels using RT-PCR and Western blotting.
  • Assessed the impact of antisense oligodeoxynucleotides (ODN) targeting the bcl-2 gene.

Main Results:

  • Testosterone withdrawal significantly increased apoptosis in SC2G cells (approx. 30% nuclei).
  • bcl-2 mRNA and protein levels decreased upon testosterone withdrawal.
  • Antisense ODN treatment reduced SC2G cell density, indicating inhibition of cell growth.

Conclusions:

  • The bcl-2 proto-oncogene actively suppresses self-programmed apoptosis in androgen-dependent cells.
  • Findings suggest potential for antisense therapy targeting bcl-2 in hormone-refractory prostate cancer, which often overexpresses Bcl-2.

Related Concept Videos